Journal Article
. 2015 Jun;33(21).
doi: 10.1200/JCO.2015.60.9271.

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

Joseph A Sparano 1 Fengmin Zhao 2 Silvana Martino 2 Jennifer A Ligibel 2 Edith A Perez 2 Tom Saphner 2 Antonio C Wolff 2 George W Sledge 2 William C Wood 2 Nancy E Davidson 2 
Affiliations
  • PMID: 26077235
  •     44 References
  •     50 citations

Abstract

Purpose: To determine long-term outcomes in a clinical trial evaluating the role of taxane type and schedule in operable breast cancer and evaluate the impact of obesity and black race on outcome.

Patients And Methods: A total of 4,954 eligible women with stage II to III breast cancer treated with four cycles of doxorubicin plus cyclophosphamide were randomly assigned to receive paclitaxel or docetaxel every 3 weeks for four doses or weekly for 12 doses using a 2 × 2 factorial design. The primary end point was disease-free survival (DFS). Results are expressed as hazard ratios (HRs) from Cox proportional hazards models. All P values are two sided.

Results: When compared with the standard every-3-week paclitaxel arm, after a median follow-up of 12.1 years, DFS significantly improved and overall survival (OS) marginally improved only for the weekly paclitaxel (HR, 0.84; P = .011 and HR, 0.87; P = .09, respectively) and every-3-week docetaxel arms (HR, 0.79; P = .001 and HR, 0.86; P = .054, respectively). Weekly paclitaxel improved DFS and OS (HR, 0.69; P = .010 and HR, 0.69; P = .019, respectively) in triple-negative breast cancer. For hormone receptor-positive, human epidermal growth factor receptor 2-nonoverexpressing disease, no experimental arm improved OS, and black race and obesity were associated with increased risk of breast cancer recurrence and death.

Conclusion: Improved outcomes initially observed for weekly paclitaxel were qualitatively similar but quantitatively less pronounced with longer follow-up, although exploratory analysis suggested substantial benefit in triple-negative disease. Further research is required to understand why obesity and race influence clinical outcome in hormone receptor-positive disease.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Paul E Goss, James N Ingle, +15 authors, Dongsheng Tu.
J Clin Oncol, 2008 Mar 12; 26(12). PMID: 18332475
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Miguel Martín, Alvaro Rodríguez-Lescure, +33 authors, GEICAM 9906 Study Investigators.
J Natl Cancer Inst, 2008 May 29; 100(11). PMID: 18505968
High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.
Pamela J Goodwin, Marguerite Ennis, +5 authors, Nicky Hood.
Breast Cancer Res Treat, 2008 Apr 26; 114(3). PMID: 18437560
Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer.
Alessia Bhargava, Xianglin L Du.
Cancer, 2009 May 20; 115(13). PMID: 19452539    Free PMC article.
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
James J Dignam, Vanja Dukic, +3 authors, Norman Wolmark.
Breast Cancer Res Treat, 2008 Oct 03; 116(3). PMID: 18830816    Free PMC article.
Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.
Idan Menashe, William F Anderson, Ismail Jatoi, Philip S Rosenberg.
J Natl Cancer Inst, 2009 Jul 09; 101(14). PMID: 19584327    Free PMC article.
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
Kathy S Albain, Joseph M Unger, +2 authors, Dawn L Hershman.
J Natl Cancer Inst, 2009 Jul 09; 101(14). PMID: 19584328    Free PMC article.
Highly Cited.
Clinical studies examining the impact of obesity on breast cancer risk and prognosis.
Rishi Jain, Howard D Strickler, Eugene Fine, Joseph A Sparano.
J Mammary Gland Biol Neoplasia, 2013 Nov 14; 18(3-4). PMID: 24221746
Review.
27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.
Erik R Nelson, Suzanne E Wardell, +10 authors, Donald P McDonnell.
Science, 2013 Nov 30; 342(6162). PMID: 24288332    Free PMC article.
Highly Cited.
Obesity and inflammation: new insights into breast cancer development and progression.
Neil M Iyengar, Clifford A Hudis, Andrew J Dannenberg.
Am Soc Clin Oncol Educ Book, 2013 May 30;. PMID: 23714453    Free PMC article.
Review.
Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
Jennifer A Ligibel, Howard D Strickler.
Am Soc Clin Oncol Educ Book, 2013 May 30;. PMID: 23714455
Review.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
Racial differences in breast carcinoma survival.
S A Joslyn, M M West.
Cancer, 2000 Jan 05; 88(1). PMID: 10618613
Racial and ethnic disparities in the receipt of cancer treatment.
Vickie L Shavers, Martin L Brown.
J Natl Cancer Inst, 2002 Mar 07; 94(5). PMID: 11880473
Highly Cited. Review.
Racial disparities in the quality of care for enrollees in medicare managed care.
Eric C Schneider, Alan M Zaslavsky, Arnold M Epstein.
JAMA, 2002 Mar 12; 287(10). PMID: 11886320
Highly Cited.
Survival of blacks and whites after a cancer diagnosis.
Peter B Bach, Deborah Schrag, +3 authors, Colin B Begg.
JAMA, 2002 Apr 23; 287(16). PMID: 11966385
Highly Cited.
African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast.
Lisa A Newman, James Mason, +4 authors, Graham A Colditz.
Cancer, 2002 Jul 13; 94(11). PMID: 12115371
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
Ann H Partridge, Philip S Wang, Eric P Winer, Jerry Avorn.
J Clin Oncol, 2003 Feb 15; 21(4). PMID: 12586795
Highly Cited.
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Annual hazard rates of recurrence for breast cancer after primary therapy.
T Saphner, D C Tormey, R Gray.
J Clin Oncol, 1996 Oct 01; 14(10). PMID: 8874335
Highly Cited.
Racial disparities in treatment and survival among women with early-stage breast cancer.
Dawn Hershman, Russell McBride, +4 authors, Alfred I Neugut.
J Clin Oncol, 2005 Sep 20; 23(27). PMID: 16170171
Comorbidity and survival disparities among black and white patients with breast cancer.
C Martin Tammemagi, David Nerenz, +2 authors, David Nathanson.
JAMA, 2005 Oct 13; 294(14). PMID: 16219879
Highly Cited.
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Kathy S Albain, William E Barlow, +18 authors, Breast Cancer Intergroup of North America.
Lancet, 2009 Dec 17; 374(9707). PMID: 20004966    Free PMC article.
Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study.
Melinda L Irwin, Catherine Duggan, +6 authors, Rachel Ballard-Barbash.
J Clin Oncol, 2010 Dec 01; 29(1). PMID: 21115859    Free PMC article.
Invasive breast cancer.
Robert W Carlson, D Craig Allred, +25 authors, National Comprehensive Cancer Network.
J Natl Compr Canc Netw, 2011 Feb 12; 9(2). PMID: 21310842
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer.
Yani Lu, Huiyan Ma, +12 authors, Leslie Bernstein.
J Clin Oncol, 2011 Jul 27; 29(25). PMID: 21788570    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Huan Jin, Dongsheng Tu, +2 authors, Paul E Goss.
J Clin Oncol, 2011 Nov 02; 30(7). PMID: 22042967    Free PMC article.
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Joseph A Sparano, Molin Wang, +9 authors, Nancy E Davidson.
J Natl Cancer Inst, 2012 Jan 18; 104(5). PMID: 22250182    Free PMC article.
Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.
Saroj Niraula, Alberto Ocana, Marguerite Ennis, Pamela J Goodwin.
Breast Cancer Res Treat, 2012 May 09; 134(2). PMID: 22562122
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.
Joseph A Sparano, Molin Wang, +10 authors, Nancy E Davidson.
Cancer, 2012 Aug 29; 118(23). PMID: 22926690    Free PMC article.
Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolism.
Evan R Simpson, Kristy A Brown.
Mol Endocrinol, 2013 Mar 23; 27(5). PMID: 23518927    Free PMC article.
Review.
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Miguel Martín, Amparo Ruiz, +27 authors, Ana Lluch.
J Clin Oncol, 2013 Jun 05; 31(20). PMID: 23733779
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.
Qian Wu, Tomonori Ishikawa, +11 authors, Philip W Shaul.
Cell Rep, 2013 Nov 12; 5(3). PMID: 24210818    Free PMC article.
Highly Cited.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Eric P Winer, Clifford Hudis, +19 authors, Mark R Somerfield.
J Clin Oncol, 2004 Nov 17; 23(3). PMID: 15545664
Highly Cited. Review.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Eleftherios P Mamounas, John Bryant, +7 authors, Norman Wolmark.
J Clin Oncol, 2005 May 18; 23(16). PMID: 15897552
Highly Cited.
American Society of Clinical Oncology position statement on obesity and cancer.
Jennifer A Ligibel, Catherine M Alfano, +13 authors, Clifford A Hudis.
J Clin Oncol, 2014 Oct 03; 32(31). PMID: 25273035    Free PMC article.
Highly Cited.
The role of taxanes in triple-negative breast cancer: literature review.
Giorgio Mustacchi, Michelino De Laurentiis.
Drug Des Devel Ther, 2015 Aug 15; 9. PMID: 26273192    Free PMC article.
Review.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer.
Neil M Iyengar, Xi Kathy Zhou, +9 authors, Andrew J Dannenberg.
Clin Cancer Res, 2015 Dec 30; 22(9). PMID: 26712688    Free PMC article.
Highly Cited.
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients.
Volker Möbus.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051389    Free PMC article.
Review.
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.
Mattea Reinisch, Beyhan Ataseven, Sherko Kümmel.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051390    Free PMC article.
Review.
Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast.
Quyen D Chu, Prakash Peddi.
Clin Med Insights Oncol, 2016 Jul 12; 10. PMID: 27398043    Free PMC article.
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.
Ippei Fukada, Kazuhiro Araki, +10 authors, Yoshinori Ito.
PLoS One, 2016 Sep 16; 11(9). PMID: 27631393    Free PMC article.
Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Effrosini G Panayotopoulou, Anna-Katharina Müller, +3 authors, Sima Lev.
Oncotarget, 2017 Feb 12; 8(28). PMID: 28187446    Free PMC article.
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.
Neil M Iyengar, Kristy A Brown, +13 authors, Andrew J Dannenberg.
Cancer Prev Res (Phila), 2017 Mar 09; 10(4). PMID: 28270386    Free PMC article.
Highly Cited.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Review.
Learning from big data: are we undertreating older women with high-risk breast cancer?
Joseph A Sparano, Hyman Muss.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721380    Free PMC article.
Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?
Boris Freidlin, Edward L Korn.
J Natl Cancer Inst, 2017 Sep 28; 109(9). PMID: 28954288    Free PMC article.
Review.
Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer.
Ying Lu, Haixin Huang, Hui Yang, Dagui Chen.
Medicine (Baltimore), 2017 Oct 12; 96(41). PMID: 29019894    Free PMC article.
Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.
Marcus Vetter, Spyridon Fokas, +6 authors, Rosanna Zanetti-Dällenbach.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088896    Free PMC article.
Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.
Fan Zhang, RuiXia LingHu, +5 authors, Junlan Yang.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108384    Free PMC article.
Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.
Qiuhong Tian, Peng Du, +3 authors, Jinsheng Zeng.
Medicine (Baltimore), 2017 Nov 16; 96(45). PMID: 29137021    Free PMC article.
Systematic Review.
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.
Carmine De Angelis, Massimo Di Maio, +12 authors, Grazia Arpino.
Oncotarget, 2018 Jan 20; 8(68). PMID: 29348868    Free PMC article.
Advances in the systemic treatment of triple-negative breast cancer.
J M Lebert, R Lester, +2 authors, J McCarthy.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910657    Free PMC article.
Highly Cited. Review.
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
Wenqi Zhou, Shizhe Chen, Faliang Xu, Xiaohua Zeng.
World J Surg Oncol, 2018 Jul 17; 16(1). PMID: 30007402    Free PMC article.
Review.
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Kathy D Miller, Anne O'Neill, +12 authors, George W Sledge.
J Clin Oncol, 2018 Jul 25; 36(25). PMID: 30040523    Free PMC article.
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Priyanka Sharma, Sara López-Tarruella, +30 authors, Miguel Martín.
Clin Cancer Res, 2018 Aug 01; 24(23). PMID: 30061361    Free PMC article.
Overview of Breast Cancer Therapy.
Tracy-Ann Moo, Rachel Sanford, Chau Dang, Monica Morrow.
PET Clin, 2018 Aug 14; 13(3). PMID: 30100074    Free PMC article.
Review.
Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer.
Nathaniel W Mabe, Douglas B Fox, +4 authors, James V Alvarez.
J Clin Invest, 2018 Aug 28; 128(10). PMID: 30148456    Free PMC article.
Obesity promotes the expansion of metastasis-initiating cells in breast cancer.
Mélanie Bousquenaud, Flavia Fico, +2 authors, Albert Santamaria-Martínez.
Breast Cancer Res, 2018 Sep 06; 20(1). PMID: 30180888    Free PMC article.
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
Florence R Wilson, Megan E Coombes, +7 authors, Chris Cameron.
Syst Rev, 2018 Nov 16; 7(1). PMID: 30428932    Free PMC article.
Systematic Review.
Taxanes for adjuvant treatment of early breast cancer.
Melina L Willson, Lucinda Burke, +3 authors, Nicholas Wilcken.
Cochrane Database Syst Rev, 2019 Sep 03; 9. PMID: 31476253    Free PMC article.
Systematic Review.
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
Amanda Fitzpatrick, Andrew Tutt.
Ther Adv Med Oncol, 2019 Nov 09; 11. PMID: 31700549    Free PMC article.
Review.
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).
Diana Lüftner, Ingo Bauerfeind, +21 authors, Marc Thill.
Breast Care (Basel), 2019 Dec 05; 14(5). PMID: 31798392    Free PMC article.
Review.
Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?
Joseph A Sparano, N Lynn Henry.
J Natl Cancer Inst, 2018 Oct 13; 111(4). PMID: 30312420    Free PMC article.
Clinical characteristics of colitis induced by taxane-based chemotherapy.
Ellie Chen, Hamzah Abu-Sbeih, +8 authors, Yinghong Wang.
Ann Gastroenterol, 2020 Jan 02; 33(1). PMID: 31892799    Free PMC article.
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.
Daniel L Hertz, Kelley M Kidwell, +9 authors, N Lynn Henry.
Clin Cancer Res, 2018 Apr 29; 24(15). PMID: 29703818    Free PMC article.
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Joseph Sparano, Anne O'Neill, +5 authors, Kathy D Miller.
JAMA Oncol, 2018 Jul 29; 4(12). PMID: 30054636    Free PMC article.
Highly Cited.
Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.
Kotha Subbaramaiah, Neil M Iyengar, +3 authors, Andrew J Dannenberg.
J Biol Chem, 2018 Nov 10; 294(1). PMID: 30409902    Free PMC article.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2019 Feb 12; 393(10179). PMID: 30739743    Free PMC article.
Highly Cited.
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Lauren A Marcath, Kelley M Kidwell, +10 authors, Daniel L Hertz.
Br J Clin Pharmacol, 2019 Dec 12; 86(5). PMID: 31823378    Free PMC article.
Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status Report.
Oleg Gluz, Cornelia Kolberg-Liedtke, Frederik Marmé, Marc Thill.
Geburtshilfe Frauenheilkd, 2020 Apr 24; 80(4). PMID: 32322109    Free PMC article.
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Anna Diana, Francesca Carlino, +5 authors, Michele Orditura.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235297    Free PMC article.
Review.
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Junjie Li, Keda Yu, +37 authors, CBCSG010 Study Group.
J Clin Oncol, 2020 Apr 11; 38(16). PMID: 32275467    Free PMC article.
Cancer Treatment Adaptations in the COVID-19 Era.
Federico Waisberg, Diego Enrico, Martín Angel, Matías Chacón.
JCO Oncol Pract, 2020 Apr 24; 16(6). PMID: 32324487    Free PMC article.
Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Hideo Shigematsu, Taizo Hirata, +2 authors, Shinji Ozaki.
Support Care Cancer, 2020 Feb 10; 28(10). PMID: 32036471    Free PMC article.
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Shani Paluch-Shimon, Nathan I Cherny, +4 authors, Fatima Cardoso.
ESMO Open, 2020 Sep 08; 5(5). PMID: 32893189    Free PMC article.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Review.
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.
Achim Wöckel, Jasmin Festl, +94 authors, Stephanie Stangl.
Geburtshilfe Frauenheilkd, 2018 Dec 26; 78(11). PMID: 30581198    Free PMC article.
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019).
Michael Untch, Christoph Thomssen, +21 authors, Nadia Harbeck.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217628    Free PMC article.
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
Andreas Schneeweiss, Carsten Denkert, +5 authors, Hans-Joachim Lück.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217629    Free PMC article.
The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Xingfa Huo, Jinming Li, +5 authors, Jiuda Zhao.
BMC Cancer, 2021 Jan 21; 21(1). PMID: 33468087    Free PMC article.
Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer.
Samilia Obeng-Gyasi, Anne O'Neill, +7 authors, Ruth C Carlos.
Cancer Med, 2020 Dec 03; 10(1). PMID: 33264502    Free PMC article.
Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.
Lihua Shang, Masaya Hattori, +4 authors, Dezheng Huo.
Breast Cancer Res, 2021 Feb 06; 23(1). PMID: 33541403    Free PMC article.
Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
M E Tesch, S K Chia, C E Simmons, N LeVasseur.
Breast Cancer Res Treat, 2021 Feb 22;. PMID: 33611678